Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.

Gordon J, Kopp JB.

Adv Chronic Kidney Dis. 2011 Jul;18(4):300-11. doi: 10.1053/j.ackd.2011.06.002. Review.

2.

Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.

Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH; NIGRAM Consortium..

Am J Kidney Dis. 2015 Feb;65(2):259-66. doi: 10.1053/j.ajkd.2014.07.022.

PMID:
25278093
4.

Therapeutic measures in proteinuric nephropathy.

Praga M.

Kidney Int Suppl. 2005 Dec;(99):S137-41. Review.

PMID:
16336567
5.

[Renin inhibition and the kidney].

Ecder T.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:28-31. Turkish.

6.

Endothelin antagonism and reversal of proteinuric renal disease in humans.

Barton M.

Contrib Nephrol. 2011;172:210-22. doi: 10.1159/000328702. Review.

PMID:
21894001
7.

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

Bianchi S, Bigazzi R, Campese VM.

Am J Kidney Dis. 2005 Jul;46(1):45-51.

PMID:
15983956
8.

V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.

Perico N, Zoja C, Corna D, Rottoli D, Gaspari F, Haskell L, Remuzzi G.

Kidney Int. 2009 Nov;76(9):960-7. doi: 10.1038/ki.2009.267.

9.
10.

Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.

Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.

Kidney Int Suppl. 2002 Dec;(82):S47-52.

11.

Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.

Slagman MC, Navis G, Laverman GD.

Curr Opin Nephrol Hypertens. 2010 Mar;19(2):140-52. doi: 10.1097/MNH.0b013e3283361887. Review.

PMID:
20051849
12.

Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.

Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G.

Am J Kidney Dis. 2009 Jan;53(1):16-25. doi: 10.1053/j.ajkd.2008.07.021.

13.

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Remuzzi G, Perico N, Macia M, Ruggenenti P.

Kidney Int Suppl. 2005 Dec;(99):S57-65. Review.

PMID:
16336578
14.

Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?

Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE.

Nephrol Dial Transplant. 1997;12 Suppl 2:53-6.

PMID:
9269701
15.

How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?

Segura J, Christiansen H, Campo C, Ruilope LM.

Curr Hypertens Rep. 2003 Oct;5(5):426-9. Review.

PMID:
12948436
16.

Aldosterone in the pathogenesis of chronic kidney disease and proteinuria.

Lu Y, Ku E, Campese VM.

Curr Hypertens Rep. 2010 Aug;12(4):303-6. doi: 10.1007/s11906-010-0116-4. Review.

PMID:
20596805
17.

Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?

Lattanzio MR, Weir MR.

Curr Hypertens Rep. 2010 Oct;12(5):369-77. doi: 10.1007/s11906-010-0142-2. Review.

PMID:
20703958
18.

Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.

von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG.

Eur J Pediatr. 2000 Aug;159(8):590-3.

PMID:
10968237
19.
20.

Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.

Benck U, Haeckel S, Clorius JH, van der Woude FJ.

Clin J Am Soc Nephrol. 2007 Jan;2(1):58-67.

Supplemental Content

Support Center